Patients deserve the BEST

DNA, RNA, MSI and PD-L1 | Somatic and Hereditary

Patients deserve the best

CIRCULOGENE provides best in class molecular and genomic tests for the Comprehensive Genomic Profiling of all solid tumors at all stages along with the novel LungLifeAI Risk Stratification test for Indeterminate Pulmonary Nodules. Circulogene provides the only CGP plasma test that combines the most advanced next-generation sequencing (NGS), Plasma PD-L1, and polymerase chain reaction (PCR) technology to detect and monitor cfDNA and cfRNA within well-characterized, well-documented, actionable cancer-associated genes.

CIRCULOGENE uses an innovative approach that has helped oncologists personalize and monitor treatment plans for over 25,000 cancer patients, with the goal of better outcomes and survival. CIRCULOGENE can complement tissue biopsy as recommended by the International Association for the Study of Lung Cancer (IASLC) for enabling a faster time to treatment, providing the right first-line treatment, and resulting in better patient outcomes.

CIRCULOGENE can complement tissue biopsy as recommended by the International Association for the Study of Lung Cancer (IASLC) for enabling a faster time to treatment, providing the right first-line treatment, and resulting in better patient outcomes.

OncoGenLDx

Including NCCN essential guideline & expert based DNA markers

Plasma cfRNA PD-L1

CIRCULOGENE offers the ONLY Plasma cfRNA PD-L1

OncoGenDx

Comprehensive tissue-based CGP for precision oncology decisions

LungLifeAI

Clinical Utility – More accurate assessment of pulmonary nodules.

Each patient’s cancer is unique, understanding the origins and severity of the cancers aids oncologists to personalize the patient’s treatment plan at the time of diagnosis and throughout their cancer journey.

The CIRCULOGENE Best-in-Class Advantage

CIRCULOGENE begins some tests with a proprietary enrichment process resulting to increase the yield of cfDNA and preserve fragile cfRNA yields. By eliminating the need for a purification step, CIRCULOGENE overcomes the limitations associated with sample volume requirements. This process preserves and extracts fragile cfRNA, enabling fusions and plasma PD-L1 to be effectively detected.

Learn More

Combined Methodologies

CIRCULOGENE utilizes both NGS and PCR to provide a comprehensive and extensive marker portfolio resulting in accurate results. Rather than limiting the analytical process by only performing NGS, the addition of PCR enables other actionable markers found in RNA mutations and fusions. By combining NGS and PCR instrumentation, CIRCULOGENE provides the breadth of DNA menu and the accuracy for RNA detection.

Learn More